RNAZTranscode Therapeutics, Inc.

Nasdaq transcodetherapeutics.com


$ 0.26 $ 0.00 (1.12 %)    

Friday, 09-Aug-2024 15:59:35 EDT
QQQ $ 450.22 $ 2.34 (0.52 %)
DIA $ 395.16 $ 0.63 (0.16 %)
SPY $ 532.81 $ 2.34 (0.44 %)
TLT $ 96.28 $ 0.94 (0.99 %)
GLD $ 224.54 $ 0.55 (0.25 %)
$ 0.2613
$ 0.26 x 1,200
-- x --
-- - --
$ 0.23 - $ 128.00
554,620
na
1.34M
$ -65.45
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-15-2024 03-31-2024 10-Q
2 04-01-2024 12-31-2023 10-K
3 11-14-2023 09-30-2023 10-Q
4 08-14-2023 06-30-2023 10-Q
5 05-15-2023 03-31-2023 10-Q
6 03-31-2023 12-31-2022 10-K
7 11-14-2022 09-30-2022 10-Q
8 08-15-2022 06-30-2022 10-Q
9 05-16-2022 03-31-2022 10-Q
10 03-31-2022 12-31-2021 10-K
11 11-15-2021 09-30-2021 10-Q
12 08-23-2021 06-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 transcode-therapeutics-13g-filing-shows-3i-lp-reported-a-99-stake-in-the-co-as-of-july-23-2024

- SEC Filing

 transcode-therapeutics-files-for-offering-of-up-to-10m-shares-of-common-stock

- SEC Filing

 why-transcode-therapeutics-rnaz-stock-is-down-60

Transcode Therapeutics shares are trading lower by 62% during Tuesday's session. The company announced pricing of its publi...

 reported-earlier-transcode-therapeutics-prices-3m-public-offering-of-10m-common-shares-at-030share

The Company intends to use the net proceeds from the offering primarily for product development activities, including one or mo...

 transcode-therapeutics-has-regained-compliance-with-nasdaqs-continued-listing-requirements

TransCode Therapeutics, Inc. (NASDAQ:RNAZ), (the "Company"), an RNA oncology company committed to more effectively trea...

 transcode-therapeutics-regains-compliance-with-minimum-bid-price-requirement-per-nasdaq-listing-rule-5550a2

- SEC Filing

 hc-wainwright--co-reiterates-buy-on-transcode-therapeutics-maintains-3-price-target

HC Wainwright & Co. analyst Emily Bodnar reiterates TransCode Therapeutics (NASDAQ:RNAZ) with a Buy and maintains $3 pri...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION